Download PDF
Fortschr Neurol Psychiatr 2017; 85(02): 92-99
DOI: 10.1055/s-0042-119862
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Prävalenz und Therapie bei Abhängigkeit von Methamphetamin („Crystal“)

Prevalence and Therapy of Crystal Methamphetamine Dependence
Michael Soyka
1   Psychiatrische Klinik, Universität München, Nussbaumstraße 7, 80336 München
2   Privatklinik Meiringen, 3860 Meiringen, Schweiz
6   Medicalpark Chiemseeblick, Rathausstraße 25, 83233 Bernau
,
Gabi Koller
1   Psychiatrische Klinik, Universität München, Nussbaumstraße 7, 80336 München
,
Lisa Proebstl
1   Psychiatrische Klinik, Universität München, Nussbaumstraße 7, 80336 München
,
Felicia Kamp
1   Psychiatrische Klinik, Universität München, Nussbaumstraße 7, 80336 München
,
Andreas Franke
5   Hochschule Neubrandenburg, (University of Applied Sciences), Brodaer Str. 2, 17033 Neubrandenburg
,
Peggy Schmidt
2   Privatklinik Meiringen, 3860 Meiringen, Schweiz
,
Gerd Baumgärtner
3   Bezirksklinik Hochstadt, Hauptstraße 13, 96272 Hochstadt am Main
6   Medicalpark Chiemseeblick, Rathausstraße 25, 83233 Bernau
,
Maik Schacht-Jablonowsky
4   AHG-Klinik Mecklenburg, Blumenstraße 3, 19217 Rehna OT Parber
,
Annegret Sievert
3   Bezirksklinik Hochstadt, Hauptstraße 13, 96272 Hochstadt am Main
,
Maximilian Straif
3   Bezirksklinik Hochstadt, Hauptstraße 13, 96272 Hochstadt am Main
,
Willem Hamdorf
4   AHG-Klinik Mecklenburg, Blumenstraße 3, 19217 Rehna OT Parber
› Author Affiliations
Further Information

Publication History

Publication Date:
24 February 2017 (online)

    Permissions and Reprints

Zusammenfassung

Nach einem kurzen Überblick über Epidemiologie und Klinik von Missbrauch und Abhängigkeit von Amphetaminen und speziell „Crystal“ werden aktuelle Konzepte zur Behandlung von Crystal-Konsumenten und Ergebnisse der Therapieforschung dargestellt. Die Wirksamkeit zweier stationärer Therapiemodelle wird dabei in einer vom BMG geförderten Studie untersucht werden. Der Studienplan wird vorgestellt. Klinische Implikationen werden diskutiert.

Abstract

Following a short overview on the epidemiology and clinical correlates of amphetamine abuse and dependence, with special emphasis on metamphetamine (“crystal”), current treatment concepts and recent results of therapy research are discussed. The efficacy of two inpatient treatment models for methamphetamine dependence are currently studied in a study funded by the German Ministry of health. The study concept is given and possible implications are discussed.

Schlüsselwörter

Drogen - Psychostimulanzien - Methamphetamin - Crystal - Sucht - Therapie

Key words

drugs - stimulants - methamphetamine - crystal - addiction - therapy
 

  • Literatur

  • 1 Soyka M. Hrsg. Drogennotfälle. Stuttgart: Schattauer; 2013
    Google Scholar
  • 2 Soyka M. Medikamentenabhängigkeit. Stuttgart: Schattauer; 2016
    Google Scholar
  • 3 Castells X. Ramos-Quiroga JA. Bosch R. et al. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database Systematic Review 2011; 6: CD007813
    PubMedGoogle Scholar
  • 4 Gouzoulis-Mayfrank E. Daumann J. Neurotoxicity of drugs of abuse – the case of methylenedioxyamphetamines (MDMA, extasy) and amphetamines. Dialogues Clin Neurosci 2009; 11: 305-317
    PubMedGoogle Scholar
  • 5 Fleckenstein AE. Volz TJ. Riddle EL. et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007; 47: 681-698
    CrossrefPubMedGoogle Scholar
  • 6 Berman S. O’Neill J. Feres S. et al. Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci 2008; 1141: 195-220
    CrossrefPubMedGoogle Scholar
  • 7 Seiden LS. Sabol KE. Metamphetamine and methxlendioxymetamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monograph 1996; 163: 251-276
    PubMedGoogle Scholar
  • 8 Koester P. Volz KG. Tittgemeyer M. et al. Decision-making in polydrug amphetamine-type stimulant users: an fMRI study. Neuropsychopharmacology 2013; 38: 1377-1386
    CrossrefPubMedGoogle Scholar
  • 9 Daumann J. Koester P. Becker B. et al. Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry. Neuroimage 2011; 54: 794-801
    CrossrefPubMedGoogle Scholar
  • 10 Simon SL. Dean AC. Cordova X. et al. Metamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. J Stud Alcohol Drugs 2010; 71: 335-344
    CrossrefPubMedGoogle Scholar
  • 11 Salo R. Nordahi TE. Buonocore MH. et al. Cognitive control and white matter callosal microstructure in metamphetamine-dependent subjects: a diffusion tensor imaging study. Biol Psychiatry 2009; 65: 122-128
    CrossrefPubMedGoogle Scholar
  • 12 Iversen L. Speed, Ecstasy, Ritalin. Amphetamine – Theorie und Praxis. Bern: Huber; 2009
    Google Scholar
  • 13 Ersche KD. Turton AJ. Chamberlain SR. et al. Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence. Am J Psychiatry 2012; 169: 926-936
    CrossrefPubMedGoogle Scholar
  • 14 Hadamitzky M. McCunney S. Markou A. et al. Development of stereotyped behaviors during prolonged escalation of metamphetamine self-administration in rats. Psychopharmacology (Berl) 2012; 223: 259-269
    CrossrefPubMedGoogle Scholar
  • 15 Kalechstein AD. Newton TF. Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 2003; 15 (02) 215-220
    CrossrefPubMedGoogle Scholar
  • 16 Bramness JG. Gundersen OH. Guterstam J. et al. Amphetamine-induced psychosis – a separate diagnostic entity or primary psychosis triggered in the vulnerable?. BMC Psychiatry 2012; 12: 221
    CrossrefPubMedGoogle Scholar
  • 17 Grant KM. LeVan TD. Wells SM. et al. Methamphetamine-associates psychosis. Journal of Neuroimmune Pharmacology 2012; 7: 113-139
    CrossrefPubMedGoogle Scholar
  • 18 Harris D. Batki SL. Stimulant psychosis: symptom profile and acute clinical course. American Journal of Addiction 2000; 9: 28-37
    CrossrefPubMedGoogle Scholar
  • 19 Hsieh JH. Stein DJ. Howells FM. The neurobiology of methamphetamine induced psychosis. Frontiers in Human Neuroscience 2014; 8: 537
    PubMedGoogle Scholar
  • 20 Lecomte T. Mueser KT. MacEwan W. et al. Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment. Journal of Nervous and Mental Diseases 2013; 201: 1085-1089
    CrossrefPubMedGoogle Scholar
  • 21 Soyka M. Sievers E. Fischer-Erlewein E. Amphetaminmissbrauch bei fraglichem adultem Aufmerksamkeitsdefizit/Hyperaktivitätssyndrom. Gesundheitswesen 2009; 71: 207-209
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Gahr M. Freudenmanna RW. Hiemke C. et al. Abuse of methylphenidate in Germany: Data from spontaneous reports of adverse drug reaction. Psychiatry Research 2014; 215: 252-254
    CrossrefPubMedGoogle Scholar
  • 23 Vocci FJ. Montova ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry 2009; 22: 263-268
    CrossrefPubMedGoogle Scholar
  • 24 EMCDDA. Europäischer Drogenbericht. Lissabon: Europäische Beobachtungsstelle für Drogen und Drogensucht; 2015
    PubMedGoogle Scholar
  • 25 United Nations Office on Drugs and Crime Vienna. World Drug Report. United Nations, New York, NY: 2013
    PubMedGoogle Scholar
  • 26 Fusillo S. Misuse and diversion of stimulants for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47: 21-31
    CrossrefPubMedGoogle Scholar
  • 27 Wilens Timothy E. Adler Lenard A. Adams J. et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry 2008; 47 (01) 21-31
    CrossrefPubMedGoogle Scholar
  • 28 Wilens TE. Fusillo S. When ADHD and substance use disorders interact: relationship and treatment implications. Curr Psychiatry Rep 2007; 9: 408-414
    CrossrefPubMedGoogle Scholar
  • 29 Daumann J. Gouzoulis-Mayfrank E. Amphetamine, Ecstasy und Designerdrogen. Stuttgart: Kohlhammer; 2015
    Google Scholar
  • 30 Neumann S. Franke AG. Soyka M. Methamphetaminkonsum in Deutschland – eine kurze Übersicht über Epidemiologie, Phänomenologie und Therapie. Nervenheilkunde (in Druck) 2016
    PubMedGoogle Scholar
  • 31 Pabst A. Kraus L. Gomes de Matos E. et al. Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht 2013; 59: 321-331
    CrossrefPubMedGoogle Scholar
  • 32 Carson DS. Taylor ER. A growing methamphetamine dependence therapeutics graveyard. Addiction 2014; 109: 1887-1888
    CrossrefPubMedGoogle Scholar
  • 33 Galloway GP. Marinelli-casey P. Stalcup J. et al. Treatment as-usual in the methamphetamine treatment project. J Psychoactive Drugs 2000; 32: 165-175
    CrossrefPubMedGoogle Scholar
  • 34 Huber A. Ling W. Shoptaw S. et al. Integrating treatments for metamphetamine abuse: a psychosocial perspective. J Addict Dis 1997; 16: 41-50
    PubMedGoogle Scholar
  • 35 Rawson RA. Shoptaw SJ. Obert JL. et al. An intensive outpatient approach for cocaine abuse treatment. The matrix model. J Subst Abuse Treat 1995; 12: 117-127
    CrossrefPubMedGoogle Scholar
  • 36 Rawson RA. Olbert JL. McCann MJ. et al. The Matrix Model Intensive Outpatient Alcohol and Drug Treatment Program: a 16-week Individualized Program. Center City, Minnesota: Hazelden; 2005
    Google Scholar
  • 37 SAMSHA. Matrix Intensive Outpatient Treatment for People with Stimulant Use Disorders. Rockville, MD: U.S. Department of Health and Human Services; 2006
    PubMedGoogle Scholar
  • 38 Pates R. Riley D. Eds Interventions for Amphetamine use. Riley publishers; 2010
    Google Scholar
  • 39 Rawson RA. Marinelli-Casey P. Anglin MD. et al. A multi-site comparison of psychosocial approaches for the treatment of metamphetamine dependence. Addiction 1994; 99: 708-717
    PubMedGoogle Scholar
  • 40 Baker A. Lee NK. Claire M. et al. Brief cognitive behavioral interventions for regular amphetamine users: a step in the right direction. Addiction 2005; 100: 367-378
    CrossrefPubMedGoogle Scholar
  • 41 Roll JM. Petry NM. Stitzer ML. et al. Contingency management for the treatment of methamphetamine use disorders. The American journal of psychiatry 2006; 163 (11) 1993-1999
    CrossrefPubMedGoogle Scholar
  • 42 Shoptaw S. Reback CJ. Peck JA. et al. Behavioral treatment approaches for metamphetamine dependence and HIV-related sexual risk behaviors among gay and bisexual men. Drug Alcohol Depend 2005; 78: 125-134
    CrossrefPubMedGoogle Scholar
  • 43 Luchansky B. Krupski A. Stark K. Treatment response by primary drug abuse: does metamphetamine make a difference?. J Subst Abuse Treat 2007; 32: 89-96
    CrossrefPubMedGoogle Scholar
  • 44 Polcin D. Bond J. Korcha R. et al. Randomized Trial of Intensive Motivational Interviewing for Metamphetamine dependence. J Addict Dis 2014; 33: 253-265
    CrossrefPubMedGoogle Scholar
  • 45 Petitjean SA. et al. A randomized controlled trial of combined cognitive-behavioral therapy plus prize-based contingency management for cocaine dependence. Drug Alcohol Depend 2014; 145: 94-100
    CrossrefPubMedGoogle Scholar
  • 46 Franke AG. Soyka M. Pharmakologisches Neuroenhancement aus Sicht der Suchtmedizin. Fortschr Neurol Psychiatr 2015; 83: 83-90
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Bundeszentrale für gesundheitliche Aufklärung. Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland 2011. Köln: Bundeszentrale für gesundheitliche Aufklärung; 2012
    Google Scholar
  • 48 Orth B. Piontec D. Kraus L. Illegale Drogen – Zahlen und Fakten zum Konsum. In: DH S. (Hrsg) Jahrbuch Sucht 2015. Lengerich: Pabst Science Publishers; 2015: 127-139
    Google Scholar
  • 49 Hamdorf W. Susemihl I. Schacht-Jablonowsky M. Katamneseergebnisse der Entwöhnungsbehandlung bei amphetaminabhängigen Patienten. Sucht Aktuell 2015; 2: 43-46
    PubMedGoogle Scholar
  • 50 Schoett K. Behandlung der Metamphetamin-Abhängigkeit. Suchtmedizin (in Druck) 2016
    PubMedGoogle Scholar
  • 51 Drogenbeauftragte der Bundesregierung, Bundesministerium für Gesundheit (BMG), Bundesärztekammer (BÄK). S3-Leitlinie Methamphetamin-bezogene Störungen, Konsultationsfassung. 2016 Available from: www.crystal-meth.aezq.de
    PubMedGoogle Scholar
  • 52 Obert JL. McCann MJ. Marinelli-Casey P. et al. The matrix model of outpatient stimulant abuse treatment: history and description. J Psychoactive Drugs 2000; 32: 157-164
    CrossrefPubMedGoogle Scholar
  • 53 Hamdorf W. et al. Crystal und Speed: Herausforderung für die Entwöhnungsbehandlung drogenabhängiger Menschen. Sucht Aktuell 2014; 21 (02) 46-48
    PubMedGoogle Scholar
  • 54 Sucht DG. Dokumentationsstandards III für die Evaluation der Behandlung von Abhängigen. Sucht 2001 47 (Sonderheft 2)
    PubMedGoogle Scholar
  • 55 Hautzinger M. Bailer M. Worall H. et al. BDI Beck-Depressions-Inventar Testhandbuch. 2., überarbeitete Auflage. Bern: Huber; 1995
    Google Scholar
  • 56 Franke GH. SCL-90-R – Die Symptom-Checkliste von L. R. Derogatis (2. vollständig überarbeitete und neu normierte Auflage). Göttingen: Beltz; 2002
    Google Scholar
  • 57 Nakovics H. Diehl A. Geiselhart H. et al. Entwicklung und Validierung eines Instrumentes zur substanzunabhängigen Erfassung von Craving: Die Mannheimer Craving Scale (MaCS). Psychiatrische Praxis 2009; 36 (02) 72-78
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Borkenau P. Ostendorf F. NEO-FFI – NEO-FÜNF-FAKTOREN INVENTAR NACH COSTA UND MCCRAE – DEUTSCHE FASSUNG (PSYNDEX Tests Review) [NEO-Fünf-Faktoren-Inventar]. Göttingen: Hogrefe; 1993
    Google Scholar
  • 59 Dutra L. Stathopoulou G. Basden SL. et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165: 179-187
    CrossrefPubMedGoogle Scholar
  • 60 Perngparn U. Lianonda B. Aramrattana A. et al. Metamphetamine dependence treatment rehabilitation in Thailand: a model assessment. J Med Assoc Thai 2011; 94: 11-117
    PubMedGoogle Scholar